Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has issued an update.
Consun Pharmaceutical Group Ltd. has called its 2026 annual general meeting for May 26 in Hong Kong, to be held in a hybrid physical and virtual format, to consider approval of the 2025 audited financial statements, director re-elections and remuneration, and the reappointment of KPMG as auditor. Shareholders will also vote on a final dividend of HKD0.40 per share for 2025 and on granting the board a general mandate to issue up to 20% of the company’s share capital, a move that could support future financing flexibility while modestly diluting existing holdings if fully used.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd. is a Cayman Islands-incorporated pharmaceutical company listed in Hong Kong, focusing on the development, manufacture and sale of pharmaceutical products. The group operates in the healthcare sector, serving patients and medical institutions in its core markets through a portfolio of prescription and related medicines.
YTD Price Performance: 1.28%
Average Trading Volume: 1,820,620
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.02B
For detailed information about 1681 stock, go to TipRanks’ Stock Analysis page.